April 18, 2021

iNews Network

News That Delivers!

Reuters exclusively reports Ocugen plans to sell 100 million Indian vaccine doses in U.S.


Reuters exclusively reported that U.S.-based biopharmaceutical firm Ocugen Inc plans to sell 100 million doses of India’s state-backed COVID-19 vaccine in the United States. Ocugen is aiming to launch the Indian-developed vaccine in the United States in the second quarter of 2021, initially with imported shots before beginning production, the firm’s chief executive Shankar Musunuri told Reuters. Ocugen had held initial talks with the U.S. Food and Drug Administration and planned to seek emergency use authorization in April. 

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: AsiaNorth America

Countries: India

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Major Global Story